1. Home
  2. WNEB vs ALXO Comparison

WNEB vs ALXO Comparison

Compare WNEB & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.70

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.51

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
ALXO
Founded
1853
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
240.8M
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
WNEB
ALXO
Price
$13.70
$1.51
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$13.67
$3.50
AVG Volume (30 Days)
30.6K
1.0M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
2.00%
N/A
EPS Growth
33.93
26.36
EPS
0.24
N/A
Revenue
$44,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.25
N/A
P/E Ratio
$56.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$0.41
52 Week High
$14.52
$2.66

Technical Indicators

Market Signals
Indicator
WNEB
ALXO
Relative Strength Index (RSI) 57.53 29.71
Support Level $13.60 $1.37
Resistance Level $14.22 $1.59
Average True Range (ATR) 0.47 0.11
MACD 0.05 -0.05
Stochastic Oscillator 89.05 0.96

Price Performance

Historical Comparison
WNEB
ALXO

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: